Lymphocyte to C-reactive protein ratio as a novel inflammatory biomarker: Validation and clinical relevance as an independent prognostic factor in cholangiocarcinoma

Table 3 Univariate and multivariate analyses of predictors of hospital stay

Variables	Univariate			Multivariate
	OR	95%CI	P value	OR	95%CI	P value
Age
> 70	1.538	0.531-4.458	0.427
Sex
Male	1.190	0.474-2.991	0.711
Obstructive jaundice
Yes	1.174	0.455-3.032	0.740
CEA
Abnormal	1.161	0.464-2.908	0.749
CA199
Normal	1.252	0.468-3.351	0.655
CA125
Abnormal	1.094	0.415-2.886	0.856
CRP
Abnormal	3.267	1.267-8.419	0.414
WBC count (109/L)
Abnormal	1.353	0.547-3.346	0.513
Albumin (g/L)
Abnormal	2.985	0.942-9.458	0.063	4.306	1.062-17.454	0.041
Hemoglobin (g/L)
Abnormal	1.696	0.632-4.551	0.294
Tumor location
Extrahepatic	1.014	0.371-2.775	0.978
Number of tumors
1	4.875	0.519-45.821	0.166
Tumor size
Largest diameter ≥ 5 cm	2.143	0.708-6.483	0.177
Surrounding vascular invasion
Yes	1.167	0.403-3.377	0.766
Surrounding tissues invasion
No	2.000	0.547-7.312	0.295
Lymph node metastasis
Yes	1.515	0.586-3.919	0.391
Tumor stage
III	1.894	0.761-4.716	0.070	1.695	0.574-5.004	0.339
Tumor grade
III vs II vs I	1.412	0.713-2.797	0.323
R0 resection
Yes	1.800	0.464-6.976	0.395
LCR
Low	4.533	1.526-13.467	0.007	8.511	2.403-30.149	0.001
Complication
Yes	3.367	1.177-9.631	0.024	8.392	2.246-31.359	0.002

OR: Odds ratio; CI: Confidence interval; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; CRP: C-reactive protein; WBC: White blood cell; LCR: Lymphocyte to C-reactive protein ratio.